IL-17作为分子佐剂增强蛋白疫苗细胞免疫应答的研究

目的:为了进一步增强重组蛋白质疫苗的细胞免疫应答,利用重组的IL-17作为分子佐剂,与卵清蛋白(ovalbumin,OVA)一起免疫小鼠,研究IL-17作为分子佐剂对适应性免疫的影响,探索IL-17对蛋白疫苗诱导的免疫反应,特别是细胞免疫应答的影响.方法:用OVA作为特异性蛋白疫苗,与不同剂量的IL-17联合免疫C57...

IL-17 as an Adjuvant Enhances Immune Responses of Recombinant Protein Vaccine

Objective: To enhance immune responses to protein vaccine, IL-17 was investigated as a molecular adjuvant to enhance humoral immune responses, especially cellular immune responses to protein vaccine. Methods: C57BL/6 mice were immunized with OVA alone, or with IL-17A by intramuscular injection. The immunization was performed on week 0, 2. The concentration of the anti-OVA IgG, the stimulated index of T lymphocyte proliferation, and the expressions of IFN-γ, IL-4 and IL-17 in CD⁺₄ T cells and IL-17, IFN-γ in CD⁺₈ T cells, and specific in vivo cytotoxic T lymphocyte (CTL) activity were detected on week 3,4. Results: The results showed that IL-17 as a molecular adjuvant for the protein vaccine, OVA, could enhance immune responses, especially the cellular immune responses. IL-17 could not only enhance the humoral responses and T cell proliferation, but also the expressions of IL-17 in CD⁺₄ and CD⁺₈ T cells, and IFN-γ in CD⁺₈ T cells. Accordingly, the level of CTL in vivo was significantly increased. Conclusion: The results demonstrated that IL-17 as a molecular adjuvant enhanced humoral and cellular immune responses to protein vaccine, especially the CD⁺₈ T cell-immunity. The novel functionality of IL-17 on adaptive immunity may lead to develop new protein vaccine targeted to the cellular immune responses.